Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from GSK

Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype

Yale's Sonnenfeld and Tian retrace presidential hopeful Vivek Ramaswamy's business record.

Fortune

GSK CEO Emma Walmsley says A.I. could improve Big Pharma's most 'profound' challenge: R&D inefficiency

"When we talk about health care costs, the single biggest thing we can do is innovate more.”

Fortune

GSK’s CEO says you need thick skin if you’re going to step into the C-suite

Emma Walmsley reflects on what it takes to lead a company through a turnaround.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Why GSK's Emma Walmsley 'violently rejects' the idea of 'superhero' CEOs

In her mind, leadership is about inspiring collaboration.

Fortune

Being 'nature-positive' has been a hollow aim. That’s about to change

Move over, greenwashing (and greenwishing). Goodbye, vague nature goals. Enter science-based nature targets.

Fortune

Giant turbines in South Ayrshire village would power Irvine pharmaceutical giant's factory

Residents debated whether to pragmatically embrace two turbines, which would power nearby GSK, planned for Dundonald.

Daily Record

RSV vaccine for pregnant women protects their newborns but is it ready for US sale?

Federal health advisers are debating a first-of-its-kind RSV vaccine to protect newborns by immunizing their moms late in pregnancy

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

Businessweek

FDA approves first vaccine for respiratory syncytial virus

The FDA has approved the first vaccine for respiratory syncytial virus (RSV).

The Hindu

FDA approves 1st RSV vaccine for older adults

After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer — especially after a virus surge that strained hospitals last fall.

Chicago Sun-Times

FDA approves 1st RSV vaccine

The Food and Drug Administration has approved a vaccine for respiratory syncytial virus (RSV) for use in people ages 60 and older.

LiveScience

World's first respiratory syncytial virus vaccine gets approval: Key points to know

Pharmaceutical company GSK's RSV vaccine has been approved by the US Food and Drug Administration (FDA) to become the world's first such vaccine. Known as Arexvy, this vaccine has been approved after three clinical trials.

The Times of India

FDA approves United States' first-ever RSV vaccine

GSK's RSV vaccine is approved for people aged 60 and older.

Axios

US approves first vaccine for RSV after decades of attempts

The US has approved the first vaccine for RSV, shots to protect older adults

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

New CBI boss says she is ‘profoundly sorry’ to women let down by group

Rain Newton-Smith’s tweets came on day she became director general at Confederation of British Industry

Evening Standard

End of the road for Covid turnover, GSK says

GSK has signalled the end of the road for its Covid drug sales boom as the pharma giant eyes fresh sources of revenue to plug the hole left by the subsidence of the pandemic.

Evening Standard

FTSE 100 Live: ‘A radical decline in UK investment’ — London Stock Exchange boss grilled on US listings

GSK, housebuilder Persimmon and the consumer products group Reckitt Benckiser are among the blue-chips updating investors today.

The Guardian - UK

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

Get all your
news in one place.

100's of premium titles.
One news app.

Insider UK

GSK workers to strike after rejecting pay offer

Workers at sites in Irvine and Montrose are set to walk out next month

Barchart

Stocks Close Slightly Higher Despite Bank Stock Weakness and Hawkish Fed Comments

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.09%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.03%. The S&P 500 and Nasdaq 100 indexes Tuesday settled...

Barchart

Stocks Fall Back on Bank Stocks and Hawkish Bullard

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.08%. U.S. stock indexes gave up early gains and are...

Evening Standard

GSK unveils £1.6 billion deal to buy Canadian medicine maker Bellus Health and its blockbuster cough drug

The deal is the biggest since the old GlaxoSmithKline split in two by separating its consumer products arm

The Philadelphia Inquirer

Dianne Feinstein is still out with shingles. Did she get GSK’s vaccine?

Dianne Feinstein’s return to the U.S. Senate has been delayed by complications from shingles. The risk of contracting that debilitating disease can be sharply reduced with the Shingrix vaccine, made by GSK, which has its U.S. headquarters in Philadelphia.

The Independent UK

Oxford malaria vaccine wins first approval from Ghana in ‘significant milestone’

600,000 die every year from the disease, mostly children in Africa

The Conversation

New asthma medicine restrictions will hurt the poorest children the most

Last week, without warning, the federal government significantly restricted the subsidy for an important and safe asthma medicine for children. A short document explained to prescribers what had changed, but gave no reasons.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.